Gilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA

MT Newswires Live06-06

Gilead Sciences (GILD) said Thursday that data from the investigational combination of bulevirtide 10 milligram with pegylated interferon alfa-2a, or PegIFN, was "superior" to investigational bulevirtide 10 mg monotherapy for the treatment of compensated chronic hepatitis delta virus infection.

The company is evaluating the efficacy and safety of bulevirtide as monotherapy and in combination with PegIFN in a phase 2b MYR204 open-label trial, Gilead added.

The data, published in the New England Journal of Medicine, demonstrated the combination of bulevirtide 10 mg with PegIFN retained a 46% rate of undetectable hepatitis delta virus RNA at week 48 after the end of the treatment, the biopharmaceutical firm said.

The safety profiles of bulevirtide in combination with PegIFN were "consistent" as compared to the individual components, the company said. Leukopenia, neutropenia, and thrombocytopenia were the most frequent adverse events, and the majority were mild to moderate.

Bulevirtide 10 mg is an investigational product and has not been approved anywhere, according to the company.

Price: 63.92, Change: +0.04, Percent Change: +0.06

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2441157597?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-06 20:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2441157597","market":"hk","top_or_hot":-1,"title":"Gilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA","media":"MT Newswires Live","content":"<html><body><p> Gilead Sciences (GILD) said Thursday that data from the investigational combination of bulevirtide 10 milligram with pegylated interferon alfa-2a, or PegIFN, was \"superior\" to investigational bulevirtide 10 mg monotherapy for the treatment of compensated chronic hepatitis delta virus infection.</p><p>The company is evaluating the efficacy and safety of bulevirtide as monotherapy and in combination with PegIFN in a phase 2b MYR204 open-label trial, Gilead added.</p><p>The data, published in the New England Journal of Medicine, demonstrated the combination of bulevirtide 10 mg with PegIFN retained a 46% rate of undetectable hepatitis delta virus RNA at week 48 after the end of the treatment, the biopharmaceutical firm said.</p><p>The safety profiles of bulevirtide in combination with PegIFN were \"consistent\" as compared to the individual components, the company said. Leukopenia, neutropenia, and thrombocytopenia were the most frequent adverse events, and the majority were mild to moderate.</p><p>Bulevirtide 10 mg is an investigational product and has not been approved anywhere, according to the company.</p><p>Price: 63.92, Change: +0.04, Percent Change: +0.06</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-06 20:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gilead Sciences (GILD) said Thursday that data from the investigational combination of bulevirtide 10 milligram with pegylated interferon alfa-2a, or PegIFN, was \"superior\" to investigational ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RNA","symbol_name":"Avidity Biosciences, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2441157597","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2441157597","pubTimestamp":1717676081,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Gilead Sciences (GILD) said Thursday that data from the investigational combination of bulevirtide 10 milligram with pegylated interferon alfa-2a, or PegIFN, was \"superior\" to investigational bulevirt","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"RNA":"Avidity Biosciences, Inc.","GILD":"吉利德科学","HDV":"iShares High Dividend Equity Fun"},"translate_title":"吉利德表示，具有PegIFN数据的Bulevirtide优于Bulevirtide单药疗法；达到46%的HDV RNA检测不到率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HDV":1,"RNA":1,"GILD":0.9},"content_text":"Gilead Sciences (GILD) said Thursday that data from the investigational combination of bulevirtide 10 milligram with pegylated interferon alfa-2a, or PegIFN, was \"superior\" to investigational bulevirtide 10 mg monotherapy for the treatment of compensated chronic hepatitis delta virus infection.The company is evaluating the efficacy and safety of bulevirtide as monotherapy and in combination with PegIFN in a phase 2b MYR204 open-label trial, Gilead added.The data, published in the New England Journal of Medicine, demonstrated the combination of bulevirtide 10 mg with PegIFN retained a 46% rate of undetectable hepatitis delta virus RNA at week 48 after the end of the treatment, the biopharmaceutical firm said.The safety profiles of bulevirtide in combination with PegIFN were \"consistent\" as compared to the individual components, the company said. Leukopenia, neutropenia, and thrombocytopenia were the most frequent adverse events, and the majority were mild to moderate.Bulevirtide 10 mg is an investigational product and has not been approved anywhere, according to the company.Price: 63.92, Change: +0.04, Percent Change: +0.06","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2441157597"}